Berlin, Germany – For individuals grappling with severe eosinophilic asthma, a chronic inflammatory disease of the airways, daily life can be profoundly disrupted. Often dismissed as a mere persistent cough, this condition can escalate into a debilitating illness that significantly impacts quality of life. Recent efforts are underway to improve access to advanced treatments and raise awareness of the challenges faced by those living with this complex disease.
Severe eosinophilic asthma is characterized by persistent airway inflammation, even with high doses of conventional therapies like inhaled corticosteroids, and bronchodilators. A key feature is an elevated level of eosinophils, a type of white blood cell, in the blood and airways, contributing to inflammation and airway hyperresponsiveness. This can lead to frequent asthma attacks, emergency room visits, and a diminished ability to participate in everyday activities. The condition differs from typical asthma in its severity and resistance to standard treatments, requiring more targeted interventions.
Understanding Severe Eosinophilic Asthma: Beyond the Cough
Asthma, in its broadest sense, affects an estimated 339 million people globally, according to the World Health Organization . However, severe eosinophilic asthma represents a subset of the disease, impacting a smaller but significantly burdened population. Professor Kim Tae-beom, an allergist at Seoul Asan Hospital, emphasizes that this isn’t simply a troublesome cough; it’s a condition that can fundamentally undermine a person’s life. He notes that the emergence of biological therapies has revolutionized treatment, offering hope to patients who previously faced limited options.
Traditionally, managing severe asthma relied heavily on oral corticosteroids. Even as effective in suppressing inflammation, long-term use of these medications carries a substantial risk of adverse effects, including diabetes, hypertension, osteoporosis, and increased susceptibility to infections. Biological therapies, specifically designed to target the underlying inflammatory pathways driving eosinophilic asthma, have emerged as a game-changer. These therapies, typically administered via injection or infusion, work by blocking specific proteins involved in the inflammatory process, reducing eosinophil levels and improving lung function.
The Challenge of Access and Affordability
Despite the advancements in treatment, significant barriers remain in ensuring equitable access to these life-altering therapies. A major hurdle is the high cost of biological medications, which can place a substantial financial burden on patients and healthcare systems. Professor Kim Tae-beom highlights the need for expanded insurance coverage and financial assistance programs to make these treatments more accessible. He also points to the necessity of a “serious illness guarantee reinforcement TF” (Task Force) established to promote awareness, engage with patient advocacy groups, and advocate for policy changes with government officials.
Currently, the process for obtaining coverage for biological therapies can be complex and time-consuming, often requiring extensive documentation and prior authorization. This can delay treatment initiation and exacerbate the burden on patients. The Korean Academy of Asthma and Allergy (KAAA) is actively working to streamline the approval process and advocate for broader coverage criteria. The goal is to ensure that patients who would benefit from these therapies are not denied access due to financial constraints or administrative hurdles.
Seoul Asan Hospital’s Leadership in Asthma Care
Seoul Asan Hospital, under the leadership of Professor Kim Tae-beom, has been at the forefront of asthma and allergy care in South Korea. Professor Kim served as the director of the Asthma/COPD Center at Seoul Asan Hospital from March 2018 to February 2024 . He also held the position of director of the Drug Surveillance Center from September 2017 to June 2020. His extensive experience and dedication to improving patient care have positioned the hospital as a leading center for the diagnosis and management of asthma and allergic diseases.
Professor Kim’s academic background includes a doctorate in medicine from Seoul National University (2006), a master’s degree in medicine from Seoul National University (2004), and a bachelor’s degree in medicine from Seoul National University (1997) . He has been a professor of allergy and immunology at Seoul Asan Hospital since 2019, contributing significantly to research and clinical advancements in the field.
The Role of the Korean Academy of Asthma and Allergy
The Korean Academy of Asthma and Allergy (KAAA) plays a crucial role in advancing the understanding and treatment of allergic diseases in South Korea. The KAAA provides clinical practice guidelines, educational resources, and supports research initiatives aimed at improving patient outcomes. Their website, allergy.or.kr, serves as a valuable resource for healthcare professionals and patients seeking information about asthma and allergies. The organization regularly updates its guidelines based on the latest scientific evidence, ensuring that clinicians have access to the most current and effective treatment strategies.
Looking Ahead: Advocacy and Innovation
The future of severe eosinophilic asthma care hinges on continued advocacy for improved access to treatment, ongoing research to develop more targeted therapies, and a commitment to raising awareness of this often-misunderstood condition. Professor Kim Tae-beom’s work with the KAAA and at Seoul Asan Hospital exemplifies this dedication. The establishment of the “serious illness guarantee reinforcement TF” signals a proactive approach to addressing the systemic challenges faced by patients with severe asthma.
Further research is needed to identify biomarkers that can predict treatment response and personalize therapy for individual patients. Exploring novel therapeutic targets and developing innovative drug delivery systems could also lead to more effective and convenient treatment options. The goal is to empower individuals with severe eosinophilic asthma to live full and active lives, free from the limitations imposed by this challenging disease.
The next step in advocating for patients will be further discussions with government officials regarding the expansion of sanjeong teukye (산정 특례), a special coverage program for serious illnesses, to include a broader range of patients with severe eosinophilic asthma. This represents a critical step towards ensuring that all those who could benefit from these life-changing therapies have access to them. We encourage readers to share this article and engage in conversations about the importance of asthma awareness and access to care.